Nifty
Sensex
:
:
25077.65
81790.12
183.40 (0.74%)
582.95 (0.72%)

Chemicals

Rating :
59/99

BSE: 530019 | NSE: JUBLPHARMA

1096.70
06-Oct-2025
  • Open
  • High
  • Low
  • Previous Close
  •  1111
  •  1124.3
  •  1088.1
  •  1119.40
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  72025
  •  79767856.6
  •  1309.9
  •  802

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 17,516.15
  • 38.76
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 18,864.25
  • 0.45%
  • 2.81

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 47.68%
  • 3.42%
  • 17.97%
  • FII
  • DII
  • Others
  • 17.4%
  • 7.16%
  • 6.37%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 2.32
  • 3.48
  • 4.82

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -0.60
  • -3.42
  • 8.62

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.92
  • 8.32
  • -27.27

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.35
  • 17.63
  • 29.66

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.01
  • 1.86
  • 1.92

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 9.96
  • 10.94
  • 13.09

Earnings Forecasts:

(Updated: 04-10-2025)
Description
2024
2025
2026
2027
Adj EPS
52.99
34.13
47.33
P/E Ratio
21.12
32.80
23.65
Revenue
7234.5
7975.47
9004.47
10077.5
EBITDA
1173.7
1345.43
1644.9
1931.7
Net Income
839.4
542.17
744.4
961.4
ROA
6.91
0.04
0.06
P/B Ratio
2.85
2.64
2.39
ROE
14.36
8.37
10.67
FCFF
-240.7
22.25
725.5
FCFF Yield
-1.28
0.12
3.85
Net Debt
1642.2
1882.7
2155
BVPS
392.62
424.75
469.05

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Net Sales
1,900.70
1,731.70
9.76%
1,928.80
1,758.60
9.68%
1,821.70
1,677.10
8.62%
1,752.30
1,680.30
4.28%
Expenses
1,611.10
1,480.20
8.84%
1,583.40
1,487.20
6.47%
1,534.30
1,459.10
5.15%
1,462.90
1,438.50
1.70%
EBITDA
289.60
251.50
15.15%
345.40
271.40
27.27%
287.40
218.00
31.83%
289.40
241.80
19.69%
EBIDTM
15.24%
14.52%
17.91%
15.43%
15.78%
13.00%
16.52%
14.39%
Other Income
12.00
14.00
-14.29%
11.90
14.40
-17.36%
9.20
35.80
-74.30%
21.70
9.90
119.19%
Interest
49.00
71.00
-30.99%
52.70
73.00
-27.81%
55.60
71.30
-22.02%
61.00
66.10
-7.72%
Depreciation
98.10
90.70
8.16%
95.20
101.00
-5.74%
91.30
94.60
-3.49%
91.40
96.60
-5.38%
PBT
154.50
499.70
-69.08%
206.10
-57.10
-
130.80
87.90
48.81%
144.50
89.00
62.36%
Tax
51.90
17.90
189.94%
54.70
8.10
575.31%
29.80
34.60
-13.87%
41.90
35.90
16.71%
PAT
102.60
481.80
-78.70%
151.40
-65.20
-
101.00
53.30
89.49%
102.60
53.10
93.22%
PATM
5.40%
27.82%
7.85%
-3.71%
5.54%
3.18%
5.86%
3.16%
EPS
6.51
30.51
-78.66%
9.72
-3.71
-
6.39
4.23
51.06%
6.51
3.96
64.39%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
7,403.50
7,234.50
6,702.90
6,281.70
6,130.16
6,098.53
9,154.41
9,110.82
7,517.84
5,861.43
5,749.13
Net Sales Growth
8.12%
7.93%
6.71%
2.47%
0.52%
-33.38%
0.48%
21.19%
28.26%
1.95%
 
Cost Of Goods Sold
2,373.50
2,317.00
2,140.70
1,877.90
1,488.01
1,536.01
3,140.58
3,521.84
2,862.51
2,002.74
2,116.20
Gross Profit
5,030.00
4,917.50
4,562.20
4,403.80
4,642.16
4,562.52
6,013.84
5,588.98
4,655.33
3,858.69
3,632.94
GP Margin
67.94%
67.97%
68.06%
70.11%
75.73%
74.81%
65.69%
61.34%
61.92%
65.83%
63.19%
Total Expenditure
6,191.70
6,060.80
5,802.10
5,505.50
4,973.83
4,702.07
7,207.34
7,371.81
5,999.45
4,516.14
4,502.19
Power & Fuel Cost
-
154.30
148.90
166.70
134.30
105.79
112.21
466.38
424.91
333.66
366.71
% Of Sales
-
2.13%
2.22%
2.65%
2.19%
1.73%
1.23%
5.12%
5.65%
5.69%
6.38%
Employee Cost
-
2,267.90
2,216.00
2,166.00
2,043.39
1,922.88
2,127.68
1,925.96
1,555.88
1,230.93
1,125.09
% Of Sales
-
31.35%
33.06%
34.48%
33.33%
31.53%
23.24%
21.14%
20.70%
21.00%
19.57%
Manufacturing Exp.
-
546.00
523.20
581.10
562.32
449.40
362.15
552.26
485.98
428.84
436.46
% Of Sales
-
7.55%
7.81%
9.25%
9.17%
7.37%
3.96%
6.06%
6.46%
7.32%
7.59%
General & Admin Exp.
-
495.20
475.00
464.10
432.34
387.92
416.80
540.75
354.56
280.98
256.23
% Of Sales
-
6.84%
7.09%
7.39%
7.05%
6.36%
4.55%
5.94%
4.72%
4.79%
4.46%
Selling & Distn. Exp.
-
205.80
214.30
161.60
209.71
177.15
194.71
267.70
247.85
185.79
135.54
% Of Sales
-
2.84%
3.20%
2.57%
3.42%
2.90%
2.13%
2.94%
3.30%
3.17%
2.36%
Miscellaneous Exp.
-
74.60
84.00
88.10
103.77
122.93
853.22
96.92
67.76
53.20
135.54
% Of Sales
-
1.03%
1.25%
1.40%
1.69%
2.02%
9.32%
1.06%
0.90%
0.91%
1.15%
EBITDA
1,211.80
1,173.70
900.80
776.20
1,156.33
1,396.46
1,947.07
1,739.01
1,518.39
1,345.29
1,246.94
EBITDA Margin
16.37%
16.22%
13.44%
12.36%
18.86%
22.90%
21.27%
19.09%
20.20%
22.95%
21.69%
Other Income
54.80
56.80
68.70
38.30
11.29
17.64
47.43
35.74
40.03
24.86
13.37
Interest
218.30
240.30
272.30
188.20
145.49
184.10
287.41
219.81
284.28
341.11
371.35
Depreciation
376.00
368.60
381.90
554.00
381.70
348.95
461.93
370.90
415.05
291.40
346.74
PBT
635.90
621.60
315.30
72.30
640.43
881.05
1,245.17
1,184.04
859.08
737.64
542.22
Tax
178.30
144.30
97.80
92.70
217.43
297.22
312.29
326.80
224.66
163.02
155.40
Tax Rate
28.04%
14.71%
66.80%
598.06%
33.95%
34.57%
25.80%
36.16%
26.15%
22.10%
28.66%
PAT
457.60
839.40
77.10
-61.00
413.94
562.87
898.24
574.46
642.81
575.66
391.83
PAT before Minority Interest
460.80
836.30
72.70
-64.90
413.02
562.61
898.24
577.01
634.42
574.63
386.82
Minority Interest
3.20
3.10
4.40
3.90
0.92
0.26
0.00
-2.55
8.39
1.03
5.01
PAT Margin
6.18%
11.60%
1.15%
-0.97%
6.75%
9.23%
9.81%
6.31%
8.55%
9.82%
6.82%
PAT Growth
-12.50%
988.72%
-
-
-26.46%
-37.34%
56.36%
-10.63%
11.66%
46.92%
 
EPS
28.73
52.69
4.84
-3.83
25.98
35.33
56.39
36.06
40.35
36.14
24.60

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
6,254.90
5,433.90
5,399.30
5,318.56
4,741.49
5,603.88
4,808.92
4,086.53
3,436.04
2,966.26
Share Capital
15.80
15.80
15.90
15.92
15.92
15.93
15.93
15.58
15.57
15.54
Total Reserves
6,224.30
5,403.60
5,377.20
5,298.98
4,724.75
5,587.95
4,792.94
4,070.78
3,419.98
2,950.72
Non-Current Liabilities
4,095.80
4,005.70
3,765.00
2,921.59
2,973.05
4,087.52
4,420.21
3,417.47
3,826.06
3,347.13
Secured Loans
237.20
299.30
265.10
200.94
20.78
728.92
811.65
729.88
1,581.96
2,620.41
Unsecured Loans
1,913.10
2,867.80
2,845.30
2,263.30
2,543.19
3,010.76
3,431.24
2,317.93
1,923.07
392.79
Long Term Provisions
119.10
100.10
92.20
95.67
94.01
150.75
114.35
107.08
80.69
70.31
Current Liabilities
2,164.60
1,889.00
1,772.40
1,591.60
1,048.83
2,619.01
2,089.73
2,004.69
1,684.04
2,464.44
Trade Payables
1,004.80
856.30
821.30
567.74
520.48
1,090.27
1,020.13
1,136.16
749.49
612.12
Other Current Liabilities
844.00
732.80
552.10
838.52
371.73
674.21
473.57
505.87
572.70
951.43
Short Term Borrowings
219.00
196.50
258.30
64.00
20.00
649.89
499.71
244.85
255.60
748.97
Short Term Provisions
96.80
103.40
140.70
121.34
136.62
204.64
96.31
117.81
106.24
151.93
Total Liabilities
12,499.00
11,315.80
10,929.20
9,829.59
8,763.40
12,310.41
11,318.96
9,457.17
8,898.75
8,739.70
Net Block
5,175.90
5,091.20
5,183.30
4,870.61
4,608.75
6,339.97
5,648.38
5,400.55
5,106.73
5,104.42
Gross Block
7,822.90
7,868.90
7,368.00
6,758.89
6,089.57
7,982.83
6,905.50
6,288.86
5,672.38
5,390.82
Accumulated Depreciation
2,647.00
2,777.70
2,184.70
1,888.28
1,480.83
1,642.85
1,257.12
888.31
565.66
286.40
Non Current Assets
8,921.80
7,439.70
7,166.80
6,320.40
5,810.90
7,272.06
6,734.16
6,267.41
5,950.63
5,864.37
Capital Work in Progress
3,630.00
2,103.10
1,561.50
1,089.57
896.99
768.39
901.43
670.97
683.78
611.32
Non Current Investment
43.50
42.20
256.40
238.60
240.96
69.36
115.11
123.52
102.71
85.43
Long Term Loans & Adv.
54.10
191.90
161.50
117.64
62.84
86.81
68.59
71.79
56.32
62.67
Other Non Current Assets
18.30
11.30
4.10
3.98
1.35
7.53
0.66
0.58
1.08
0.53
Current Assets
3,509.70
3,632.20
3,762.40
3,509.19
2,952.50
5,038.35
4,584.80
3,189.76
2,948.12
2,875.32
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
1,129.20
1,289.60
1,380.50
1,254.87
1,129.38
1,845.38
1,417.39
1,391.39
1,220.40
1,203.10
Sundry Debtors
891.50
915.90
961.20
927.99
819.90
1,293.22
1,271.55
1,130.76
1,005.30
950.50
Cash & Bank
1,088.80
956.80
1,014.30
984.24
671.32
1,399.87
1,370.41
248.79
459.63
344.58
Other Current Assets
400.20
241.90
135.10
110.93
331.90
499.88
525.44
418.81
262.79
377.13
Short Term Loans & Adv.
246.30
228.00
271.30
231.17
89.53
80.29
39.80
45.75
37.06
133.06
Net Current Assets
1,345.10
1,743.20
1,990.00
1,917.59
1,903.67
2,419.34
2,495.07
1,185.06
1,264.08
410.88
Total Assets
12,431.50
11,071.90
10,929.20
9,829.59
8,763.40
12,310.41
11,318.96
9,457.17
8,898.75
8,739.69

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
1,072.10
971.30
660.70
837.54
1,784.27
1,542.94
1,121.51
1,303.20
1,268.49
1,098.89
PBT
980.60
170.50
27.80
630.45
1,212.01
1,210.53
903.81
859.08
737.64
542.22
Adjustment
218.10
755.40
782.90
579.47
716.48
760.74
861.53
687.81
637.90
737.89
Changes in Working Capital
111.80
253.10
54.30
-178.29
249.90
-179.67
-300.53
14.15
36.88
-133.16
Cash after chg. in Working capital
1,310.50
1,179.00
865.00
1,031.63
2,178.39
1,791.60
1,464.82
1,561.04
1,412.42
1,146.96
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-238.40
-207.70
-204.30
-194.09
-394.12
-248.66
-343.31
-257.84
-143.94
-48.07
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
487.70
-607.90
-544.40
-380.37
-739.01
-327.00
-1,011.84
-617.70
-450.39
-312.53
Net Fixed Assets
-9.50
-51.10
-92.16
-752.97
2,198.22
-241.66
-305.67
-147.58
-115.33
785.60
Net Investments
-0.10
-0.30
-10.85
0.23
118.05
-0.14
-57.59
3.34
-0.39
57.01
Others
497.30
-556.50
-441.39
372.37
-3,055.28
-85.20
-648.58
-473.46
-334.67
-1,155.14
Cash from Financing Activity
-1,452.70
-432.50
-156.70
-32.60
-1,709.39
-1,050.37
657.43
-901.13
-685.87
-842.75
Net Cash Inflow / Outflow
107.10
-69.10
-40.40
424.57
-664.13
165.56
767.10
-215.63
132.22
-56.38
Opening Cash & Equivalents
956.40
1,013.90
983.80
501.96
1,230.81
1,005.40
244.18
456.44
339.27
391.64
Closing Cash & Equivalent
1,088.30
956.40
1,013.90
983.82
501.96
1,230.81
1,005.40
244.18
456.44
339.27

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
394.94
343.00
339.19
333.91
297.84
351.83
301.93
262.33
220.61
190.90
ROA
7.02%
0.65%
-0.63%
4.44%
5.34%
7.60%
5.55%
6.91%
6.52%
4.46%
ROE
14.35%
1.34%
-1.21%
8.21%
10.88%
17.25%
12.97%
16.87%
17.95%
14.27%
ROCE
13.92%
5.02%
2.53%
9.97%
11.89%
15.07%
13.06%
15.21%
14.44%
12.42%
Fixed Asset Turnover
0.92
0.88
0.89
0.95
0.87
1.23
1.38
1.26
1.09
0.92
Receivable days
45.59
51.11
54.89
52.04
63.24
51.13
48.12
51.58
59.43
54.81
Inventory Days
61.02
72.70
76.56
70.98
89.02
65.05
56.26
63.07
73.64
75.51
Payable days
146.59
143.02
134.99
133.47
191.38
58.75
55.42
56.86
54.84
53.44
Cash Conversion Cycle
-39.98
-19.21
-3.54
-10.45
-39.12
57.43
48.96
57.79
78.23
76.88
Total Debt/Equity
0.39
0.63
0.63
0.55
0.55
0.83
1.01
0.85
1.18
1.51
Interest Cover
5.08
1.63
1.15
5.33
5.67
5.21
5.11
4.02
3.16
2.46

News Update:


  • USFDA completes PADE inspection of Jubilant Pharmova’s arm
    22nd Sep 2025, 10:23 AM

    The inspection closed with no observations

    Read More
  • Jubilant Pharmova completes transfer of API business to Jubilant Biosys
    2nd Sep 2025, 11:58 AM

    The company had received approval from board of directors of the company on June 12, 2025 for the same

    Read More
  • USFDA concludes PAI at Jubilant Pharmova’s arm's facility at Roorkee
    2nd Aug 2025, 16:10 PM

    The USFDA has issued 4 observations pursuant to the completion of audit

    Read More
  • Jubilant Pharmova - Quarterly Results
    29th Jul 2025, 13:35 PM

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.